Ministry of Food and Drug Safety Approves Clinical Trial Plan on Simultaneous Injection of New Drug with ‘Keytruda’ for Gastric
MedPacto, a subsidiary of TheragenEtex, acquired approval from Ministry of Food and Drug Safety on phase 1b-2a clinical trial plan to simultaneously inject new anticancer drug ‘Vactosertib (TEW-7197)’ currently under development and Keytruda (substance name: Pembrolizumab) of MSD.
This clinical trial targets gastric cancer or colorectal cancer patient who received 2 or more anticancer treatments but experienced no effectiveness, and the subject includes patient suffering from diffuse gastric cancer, gastroesophageal junction adenocarcinoma, and some subtypes of colorectal cancer (CMS type 4), which indicates low cure rate in current anticancer treatments.
‘Vactosertib’ selectively suppresses signal transduction transforming growth factor β, which is known to hinder effectiveness of immunotherapeutic anticancer drugs.
This new drug improves the environment surrounding tumors allowing immunocyte to effectively eliminate cancer cells, which allows cure effectiveness and enhance response rate when injected simultaneously with immunotherapeutic anticancer drug.
In addition, MedPacto recently signed a contract for domestic clinical trial on simultaneous injection of ‘Vactosertib’ and ‘Durvalumab (product name: Imfinzi)’ with AstraZeneca.